Trachoma Medication

  • Author: Anthony W Solomon, MBBS, DTM&H, PhD, MRCP; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: May 19, 2011
 

Medication Summary

The aim in treatment is to reduce the amount C trachomatis in the infection reservoir in the family. Treating an individual and not treating infected family members leaves the individual at risk for repeat infection. All family members, including infants, should be treated.

The antibiotic of choice for treating active trachoma is azithromycin. The dose for children is 20 mg/kg in a single dose; adults receive a single dose of 1 g. The second-line treatment is topical tetracycline eye ointment 1%. Topical tetracycline is applied to both eyes twice a day for 6 weeks.

If the patient lives in a hyperendemic area, the whole district (or whole community) is eligible for antibiotic treatment.

Next

Antibiotics

Class Summary

Antibiotic therapy is part of the WHO SAFE strategy for trachoma.

View full drug information

Azithromycin (Zithromax)

 

Macrolide antibiotic; DOC for trachoma. Plasma concentrations are low, but tissue concentrations are higher, giving it value in treating intracellular organisms. Long tissue half-life. Single dose recommended.

View full drug information

1% Tetracycline ointment (Achromycin)

 

Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit. Use if azithromycin is unavailable. Minimal systemic adverse effects.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Anthony W Solomon, MBBS, DTM&H, PhD, MRCP  Specialist Registrar in Infectious Diseases and Tropical Medicine, The Hospital for Tropical Diseases, London; Lecturer, International Centre for Eye Health, Clinical Research Unit, London School of Hygiene and Tropical Medicine, London

Anthony W Solomon, MBBS, DTM&H, PhD, MRCP is a member of the following medical societies: Royal College of Physicians of the United Kingdom and Royal Society of Tropical Medicine and Hygiene

Disclosure: Pfizer Inc Grant/research funds Researcher; International Trachoma Initiative Grant/research funds Researcher; Pfizer Inc Support to attend the Trachoma Scientific Exchange in Phoenix, 2006 Speaking and teaching; International Trachoma Initiative Member of Trachoma Expert Committee None

Coauthor(s)

Hugh Ringland Taylor AC, MD, MBBS, BMedSc (Melb), DO (Melb), FRACO, FRACS, FAAO, FACS, FAICD  Harold Mitchell Professor of Indigenous Eye Health, Melbourne School of Population Health, University of Melbourne

Hugh Ringland Taylor AC, MD, MBBS, BMedSc (Melb), DO (Melb), FRACO, FRACS, FAAO, FACS, FAICD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Specialty Editor Board

Anastasios J Kanellopoulos, MD  Assistant Program Director, Clinical Associate Professor, Department of Ophthalmology, Manhattan Eye, Ear, and Throat Hospital, New York University

Anastasios J Kanellopoulos, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Eye Bank Association of America, and International Society of Refractive Surgery

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD  Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD  Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Institute

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology

Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching; EyeGate Pharma Consulting; Inspire Consulting fee Consulting; Bausch & Lomb Honoraria Speaking and teaching; Bausch & Lomb Consulting fee Consulting

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References

  1. Bobo LD, Novak N, Munoz B, Hsieh YH, Quinn TC, West S. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis. Dec 1997;176(6):1524-30. [Medline].

  2. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65(4):477-83. [Medline].

  3. Kalua K, Chirwa T, Kalilani L, Abbenyi S, Mukaka M, Bailey R. Prevalence and risk factors for trachoma in central and southern Malawi. PLoS One. Feb 5 2010;5(2):e9067. [Medline].

  4. Baker MC, Mathieu E, Fleming FM, et al. Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. Lancet. Jan 16 2010;375(9710):231-8. [Medline].

  5. Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev. Mar 16 2011;3:CD001860. [Medline].

  6. West S, Munoz B, Lynch M, Kayongoya A, Chilangwa Z, Mmbaga BB, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. Jan 21 1995;345(8943):155-8. [Medline].

  7. Reacher M, Foster A, Huber J. Trichiasis surgery for trachoma: the bilamellar tarsal rotation procedure. WHO/PBL 93.29. Geneva: World Health Organization;. 1993.

  8. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis. Mar 1997;24(3):363-8. [Medline].

  9. Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis. Nov-Dec 1985;7(6):717-25. [Medline].

  10. Mabey DC, Solomon AW, Foster A. Trachoma. Lancet. Jul 19 2003;362(9379):223-9. [Medline].

  11. Solomon A, Burton M. What's new in azithromyin?. Community Eye Health. Dec 2004;17(52):54-6. [Medline].

  12. Taylor HR, Johnson SL, Schachter J, Caldwell HD, Prendergast RA. Pathogenesis of trachoma: the stimulus for inflammation. J Immunol. May 1 1987;138(9):3023-7. [Medline].

 
Previous
Next
 
Trachomatous inflammation, follicular (TF), is the presence of 5 or more follicles (each at least 0.5 mm in diameter) on the central part of the upper tarsal conjunctiva. Images from the Slides/Text Teaching Series, No. 7, Trachoma, published by The International Centre for Eye Health, Institute of Ophthalmology, 11-43 Bath St, London EC1V 9EL, United Kingdom. Photograph courtesy of John D. C. Anderson, MD.
Trachomatous inflammation, intense (TI) is pronounced inflammatory thickening of the upper tarsal conjunctiva that obscures more than one half the normal deep tarsal vessels. Photograph courtesy of Allen Foster, MD.
Trachomatous conjunctival scarring (TS) is the presence of easily visible scars in the tarsal conjunctiva.
Trachomatous trichiasis (TT) is defined as the presence of at least 1 eyelash rubbing on the eyeball or evidence of recent removal of in-turned lashes. Photograph courtesy of John D. C. Anderson, MD.
Easily visible corneal opacity over the pupil; it is so dense that at least part of the pupil margin is blurred when viewed through the opacity. Photograph courtesy of John D. C. Anderson, MD.
The image on the left shows intense inflammatory trachoma, and the image on the right shows allergic conjunctivitis with the typical cobblestone papillae. Courtesy of John D. C. Anderson, MD, and Murray McGavin, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.